A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights.

Khanani AM, Vajzovic L, Bakall B, Chavali VRM, Qamar H

DOI: 10.1038/s41433-025-04202-5
Published: 2026 Feb
Container: Eye (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41433-025-04202-5,
  title = {A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights.},
  author = {Khanani AM and Vajzovic L and Bakall B and Chavali VRM and Qamar H},
  year = {2026},
  journal = {Eye (London, England)},
  doi = {10.1038/s41433-025-04202-5},
  url = {https://doi.org/10.1038/s41433-025-04202-5}
}

RIS

TY  - JOUR
TI  - A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights.
AU  - Khanani AM
AU  - Vajzovic L
AU  - Bakall B
AU  - Chavali VRM
AU  - Qamar H
PY  - 2026
JO  - Eye (London, England)
DO  - 10.1038/s41433-025-04202-5
UR  - https://doi.org/10.1038/s41433-025-04202-5
ER  -

APA

AM, K., L, V., B, B., VRM, C., & H, Q. (2026). A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights.. Eye (London, England). https://doi.org/10.1038/s41433-025-04202-5

Source records

pubmed · retrieved 2026-09-26T04:54:05.785Z